Nine-month sales of €4.4 million, up 21% as reported and 24% at constant exchange rates (CER)
Europe and Rest of World up 128%, led by CellTolerance®, now present in 9 countries with 27 paying centers, up from 17 at end-2025
Third-quarter sales of €1.2 million, down 11% at CER, reflecting temporary U.S. organization vacancies, fully resolved in October with all four territories now staffed
TaeWoong partnership enters execution phase, actively engaging priority U.S. target accounts
Financial resources to fund operations until the end of 2027
Investor videoconference at 6:00 p.m. CEST – French Session: Registration link
Paris and Boston, October 20, 2026 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reports its sales for the third quarter and the first nine months of 2026.
“Over nine months our sales grew 24% at constant exchange rates with international sales up 128% and recurring revenue up 17%. In the United States we are selling at higher prices and lower discounts than at any point since 2023, and systems placed since 2025 already generate 46% of our probe sales. The third quarter was held back by two unstaffed U.S. territories. Those roles are now filled, every territory has both a Territory Manager and a Clinical Associate, and our partnership with TaeWoong is operational. We head into our historically strongest fourth quarter fully staffed across all territories and with a solid pipeline skewed toward high-value system sales,” commented Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies.
